Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2016

View Archived Issues

Braeburn and Camurus expand collaboration and license agreement

FDA clears Cedars-Sinai to test combination stem cell gene therapy for ALS

NanoCarrier assumes responsibility for epirubicin micelle development

Sareum completes feasibility study of TYK2 inhibitors to treat T-ALL

FDA puts partial clinical hold on enrollment in LADD trials

Sunovion Pharmaceuticals completes acquisition of Cynapsus Therapeutics

Novel pathogenic mechanism in C9ORF72-related ALS and FTD

Bioblast Pharma reports results for phase I trial of trehalose

Melinta Therapeutics submits NDA to FDA for Baxdela

FDA and EC grant orphan drug designation to Solid Biosciences' SGT-001

Gpr17-targeted approaches as novel therapeutic options in demyelination diseases

FDA clears IND for phase I trials of XMT-1522

DBV reports topline results from 2-year follow-up study of Viaskin Peanut

EMA issues positive opinion recommending orphan drug designation for La Jolla's LJPC-401

Investigators patent pfDHODH inhibitors

Chinese scientists disclose IDO1 inhibitors

Mutabilis describes beta-lactamase inhibitors

FDA grants fast track designation to ATYR-1940 for FSHD

Japanese researchers develop RISK-1 and/or PKB beta/Akt2 inhibitors

U.S. scientists present RAS GTPases inhibitors

FDA places clinical hold on phase III program for Inovio's VGX-3100

FDA issues new approvals in NSCLC for Keytruda

New [18F]fluorinated PSMA agents show potential for PET imaging of prostate cancer

Advaxis announces stage 2 results from phase II trial of axalimogene filolisbac in cervical cancer

New phase II trial explores use of anti-EGFR-IL-dox in triple-negative EGFR-positive breast cancer

BioCardia merges with Tiger X Medical

Genetic variants in genes related to pain sensitivity may have a role in EDS

Investigators identify novel mutations in Pompe disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...